In March 2025, Shanghai's Ruijin Hospital performed China's first GCP-standard iPSC cell transplant for Parkinson's disease. The 6-month results are published — here's an honest look.
On March 1, 2025, a team at Shanghai Ruijin Hospital — in collaboration with the Center for Excellence in Brain Science and Intelligence Technology at the Chinese Academy of Sciences — performed China's first autologous iPSC-derived cell transplant for Parkinson's disease under Good Clinical Practice (GCP) standards.
What Happened at Ruijin Hospital
On March 1, 2025, a team at Shanghai Ruijin Hospital — in collaboration with the Center for Excellence in Brain Science and Intelligence Technology at the Chinese Academy of Sciences — performed China's first autologous iPSC-derived cell transplant for Parkinson's disease under Good Clinical Practice (GCP) standards.
The patient was a 66-year-old woman with Parkinson's disease. The procedure involved transplanting dopaminergic neural precursor cells — derived from her own reprogrammed stem cells (iPSCs) — into specific regions of her brain via a minimally invasive stereotactic approach.
The therapy product, UX-DA001, was developed by Unixell Biotech, a Shanghai-based company.
The Published Results
Six-month outcomes, reported by the Shanghai Municipal Government and covered in China Daily (April 2025):
- Motor function (MDS-UPDRS Part III, OFF state): improved by 21 points — a 47.7% improvement
- Motor function (MDS-UPDRS Part III, ON state): improved by 8 points — a 42.1% improvement
- Functional outcome: Patient regained ability to walk independently for an entire day
- Safety: Favorable safety profile at 6 months; no serious adverse events reported
The MDS-UPDRS Part III is the standard international scale for measuring Parkinson's motor symptoms. An improvement of 20+ points in this scale is generally considered clinically meaningful.
How to Read This Data Honestly
This is a single-patient case study. It is not a controlled clinical trial with a comparison group. Results from one patient cannot be generalized to a population, and 6 months is an early timepoint for a neurodegenerative condition — longer follow-up is needed to assess durability.
What makes this result notable is the mechanism: autologous iPSC-derived therapy means the cells come from the patient's own tissue, which eliminates immune rejection risk — a major limitation of allogeneic (donor) cell approaches. The use of GCP standards means the data is collected rigorously and can inform future trials.
The Broader Context in China
Approximately 4 million people in China live with Parkinson's disease — the largest Parkinson's population in the world. This has driven significant research investment. China has multiple ongoing neurology cell therapy trials, including:
- XS228 (XellSmart Biopharmaceutical): iPSC-derived cell therapy for ALS — China's first nationally registered iPSC-derived clinical study, with FDA Phase I approval also granted for ALS and spinal cord injury
- Multiple MSC-based trials for peripheral neuropathy and stroke recovery
What International Parkinson's Patients Should Know
The Ruijin Hospital iPSC procedure is not currently available as a standard treatment. It was conducted as part of a registered clinical research program. Patients interested in neurological cell therapy in China should look for:
- Hospitals with neurology departments ranked in China's top 10 (Fudan University Rankings)
- Registered trial numbers on China's CDE clinical trial registry or WHO ICTRP
- Teams with published peer-reviewed research in neurology
Panda Touring Care works with partner hospitals in Beijing and Shanghai with active neurology research programs. Contact us for a medical record review and eligibility assessment.
Sources: China Daily, April 10, 2025; Shanghai Municipal Government official report, April 2025; XellSmart PR Newswire, 2024.